SAFC has coupled its chiral screening and small-scale purification services to meet what it says is a boom in demand for more complete chemical analysis from drugmakers.
Catalent has upgraded its North Carolina, US, sterile development and analytics plant to increase its aseptic fill-finish activities four-fold in a bid to boost its integrated biologics offering.
US CRO Pharmaceutical Product Development (PPD) predicts that new CEO Dave Simmons' ‘pharmaceutical industry experience’ gained at Pfizer will be an asset in guiding partnerships.
The US FDA will have more powers to inspect ‘risky’ overseas pharmaceutical plants according to supporters of a bill being considered by the US senate this week.
EMD Millipore premiered a new single-use bioreactor at Interphex 2012, claiming the new design addresses industry demand for ease of use and flexibility.
Royal DSM NV has confirmed that Percivia – its biosimilars joint venture (JV) with Crucell - is to cease in-house product development after failing to agree on future investment and says that job losses are likely.
Australian preclinical CRO vivoPharm has bought toxicology testing firm RMIT Drug Discovery Technologies (RDDT) and will relocated to a new Melbourne HQ.
RNA therapeutics developer Arrowhead Research has bought Alvos Therapeutics in the hope that peptide targeting technology will help it overcome delivery challenges.
Pharmas and biopharmas should adopt a “nimble”, more flexible approach when building relationships with CROs to stay ahead of the changing market, according to a new report.
The FDA says it expects more boards to join an inter-regulatory API (active pharmaceutical ingredient) inspection programme after simplifying the sign-up process.
Bend Research has launched a formulation and production optimisation service for botherapeutics and vaccine makers, leveraging techs developed with Big Pharma partners.
March has already been a busy month for the biomanufacturing technology sector and here is in-Pharmatechnologist.com’s round-up of some of the developments so far.
Formac Pharmaceuticals and WR Grace say their silica platform can improve the formulation selection process for poorly soluble APIs (active pharmaceutical ingredients).
The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.
GlaxoSmithKline (GSK) and Astrazeneca have each funded new nuclear magnetic resonance (NMR) research at the University of Warwick, UK which could improve the QC process for drugsmakers.
Pierrel Research is close to inking a takeover deal with Swiss R&D firm monoBIOTECH that it says will help shape“the new paradigm of the drug discovery and development process.”
Celerion and Ricera Biosciences have launched a new joint venture to provide a cost-cutting one-stop-shop solution for companies developing and commercialising biosimilars.
